Veracyte to Participate in Upcoming Investor Conferences

Veracyte (VCYT) will participate in three investor conferences in November, with fireside chats available through live audio webcasts.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Veracyte (VCYT) will participate in three investor conferences in November, with fireside chats available through live audio webcasts.

The chats are scheduled for UBS in Palm Beach Gardens on November 10 at 4:15 p.m. Eastern Time; Jefferies in London on November 18 at 2:30 p.m. Greenwich Mean Time; and Stephens in Nashville on November 19 at 9:30 a.m. Central Time. Webcast replays will remain available for 90 days after each presentation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/29/2026 - 04:05 PM EDT

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will be participating in the following investor conferences:

UBS Global Healthcare Conference – Palm Beach Gardens, FL
Fireside chat on Tuesday, November 10 at 4:15 p.m. Eastern Time
Jefferies Global Healthcare Conference – London, UK
Fireside chat on Wednesday, November 18 at 2:30 p.m. Greenwich Mean Time
Stephens Annual Investment Conference – Nashville, TN
Fireside chat on Thursday, November 19 at 9:30 a.m. Central Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast.

About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).